SBRT for oligometastatic recurrence

Although the theory of the existence of a temporarily stable oligometastatic stage in prostate cancer is more than 20 years old, it remains unknown whether there is any benefit to pursuing curative or progression-delaying radiation (or indeed other forms of targeted treatment) if there are only a few metastases detected at recurrence. … READ MORE …

Longer time between treatments reduces SBRT rectal toxicity

There are many details of stereotactic body radiation therapy (SBRT) that may be optimized over the coming years. Among them is the optimum treatment schedule — i.e., how far apart should the treatments be spaced? … READ MORE …

SBRT for high-risk prostate cancer

Treatments for high-risk prostate cancer are limited. Surgery is usually considered a poor option if the cancer has already escaped the prostate capsule (stage T3/4). External beam radiation is often given with hormone therapy for high grade cancers, or with a brachytherapy boost. … READ MORE …

7-year outcomes data after treatment with SBRT

A new article in Frontiers in Oncology now provides us with data from the median 6-year follow-up of > 450 men with prostate cancer treated with stereotactic body radiation therapy (SBRT) using the CyberKnife technology. … READ MORE …

Risk for GU side effects higher after SBRT than after IMRT?

A recent, retrospective analysis of Medicare data suggests that men who have first-line stereotactic body radiation therapy (SBRT) are at somewhat higher risk for genitourinary (GU) side effects than men who select intensity-moduated radiation therapy (IMRT). … READ MORE …

Medium-term outcome data on CyberKnife SBRT for localized prostate cancer

A paper in the May issue of the journal Radiation Oncology has provided 6-year outcome data (including quality of life and complications of treatment) after the use of stereotactic body radiation therapy (SBRT) using the CyberKnife system (from the Flushing Radiation Oncology group in Flushing, New York). … READ MORE …

CyberKnife radiation in treatment of intermediate-risk prostate cancer

A new paper in the journal Radiation Oncology provides data on a series of 41 men treated with stereotactic body radiation therapy for intermediate-risk prostate cancer. … READ MORE …

SBRT in men with intermediate-risk, localized prostate cancer

Data reported by Meier et al. and presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) provide some early guidance on the efficacy and safety of sterotactic body radiation therapy (SBRT) in treatment of men with intermediate-risk, localized prostate cancer. … READ MORE …

Data from large, retrospective study shows 5-year efficacy for SBRT in localized prostate cancer

Data from a large, retrospective, multi-center study of stereotactic body radiation therapy (SBRT) with CyberKnife technology in the treatment of men with localized prostate cancer were presented on Wednesday afternoon at the annual meeting of the American Society for Radiation Oncology (ASTRO). … READ MORE …

Additional 5-year follow-up data on SBRT for localized prostate cancer

In February this year we reported initial 4- and 5-year follow-up data from two US-based research teams on the use of stereotactic body radiation therapy (SBRT or CyberKnife radiation) as a treatment for prostate cancer. A new study from a Korean research group appears to confirm the earlier findings. … READ MORE …

Age, exercise, and ADT: effects on health and fitness in prostate cancer patients

While there is general consensus that exercise helps to minimize the impact of androgen deprivation therapy (ADT) on body composition, fitness, and other factors, there is limted evidence from clinical trials about the specific types of exercise that may be of greatest value. … READ MORE …